Ethan Hoffmann
Sage Group
13 Papers
10 Citations
Ethan Hoffmann is an academic researcher from Sage Group. The author has contributed to research in topics: Neuroactive steroid & Allosteric regulation. The author has an hindex of 7, co-authored 13 publications.
Chat about Author
Papers
Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial
Stephen Kanes,Helen Colquhoun,H. Gunduz-Bruce,Shane Raines,Ryan Arnold,Amy Schacterle,James J. Doherty,C. Neill Epperson,Kristina M. Deligiannidis,Robert Riesenberg,Ethan Hoffmann,David R. Rubinow,Jeffrey Jonas,Steven M. Paul,Samantha Meltzer-Brody +14 more
TL;DR: In women with severe post-partum depression, infusion of brexanolone resulted in a significant and clinically meaningful reduction in HAM-D total score, compared with placebo, which supports the rationale for targeting synaptic and extrasynaptic GABAA receptors in the development of therapies for patients with post- partum depression.
383
Neuroactive Steroids. 2. 3α-Hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1′-yl)-19-nor-5β-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (γ-Aminobutyric Acid)A Receptor
Gabriel Martinez Botella,Francesco G. Salituro,Boyd L. Harrison,Richard Thomas Beresis,Zhu Bai,Maria-Jesus Blanco,Gabriel M. Belfort,Jing Dai,Carlos M. Loya,Michael A. Ackley,Alison L. Althaus,Scott J. Grossman,Ethan Hoffmann,James J. Doherty,Albert J. Robichaud +14 more
TL;DR: The discovery of 3α-hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5β-pregnan-20-one (SAGE-217, 3), a potent GABAA receptor modulator at both synaptic and extrasynaptic receptor subtypes, with excellent oral DMPK properties is reported.
116
Brexanolone as adjunctive therapy in super‐refractory status epilepticus
Eric Rosenthal,Jan Claassen,Mark S. Wainwright,Aatif M. Husain,Henrikas Vaitkevicius,Shane Raines,Ethan Hoffmann,Helen Colquhoun,James J. Doherty,Stephen Kanes +9 more
TL;DR: A multicenter, phase 1/2 study in SRSE patients to evaluate the safety and tolerability of brexanolone (USAN; formerly SAGE‐547 Injection), a proprietary, aqueous formulation of the neuroactive steroid, allopregnanolone.
90
Patent
Neuroactive steroids and their methods of use
Ethan Hoffmann,George G. Nomikos,Handan Gunduz-Bruce,Stephen J. Kanes +3 more
- 07 Sep 2018
TL;DR: In this article, the authors have discussed the effectiveness of the administration of Compound 1 for treating CNS related disorders, e.g., tremor, depression, and anxiety disorder.
4